LOS ANGELES, December 15, 2022 /PRNewswire/ — Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor-natural killer T cell (CAR-NKT) therapies for cancer patients, today announced the appointment of Robert S Negrin, MD, to its Scientific Advisory Board. dr Negrin is one of the world’s leading experts in hematology and cellular immunology and joins the scientific founders of Appia Bio to advise on the company’s research and development.
Appia Bio is focused on discovering and developing commercial allogeneic cell therapies for a broad range of cancer indications, leveraging a scalable technology platform with the goal of improving patient access. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio harnesses the biology of lymphocyte development with CAR and T cell receptor (TCR) genetic engineering to generate CAR-expressing innate invariant NKT cells from healthy donor stem cells.
“We are very pleased that Dr. Negrin joins our world-class Appia Bio Scientific Advisory Board. He brings a wealth of knowledge in the fields of cellular immunology, cell therapy and NKT biology, as well as strong clinical expertise in hematology and bone marrow transplantation. Dr Negrin’s experience will be a great asset to Appia Bio as we fulfill our mission to develop novel anti-cellular cancer drugs with curative potential that are widely accessible to patients,” he said Jeff WiezorekMD, Chief Medical Officer at Appia Bio.
dr Negrin is a professor of medicine and former head of the department of blood and bone marrow transplantation University at Stanford. His research focused on cellular immunology, specifically developing a more fundamental understanding of complex biological responses such as graft-versus-host and graft-versus-tumor responses, with a focus on immunoregulatory mechanisms.
dr Negrin has authored more than 225 original papers, 40 book chapters and one book, received a number of awards including the Doris Duke Distinguished Clinical Scientist Award, and is a member of the Association of American Physicians. He previously served as President of the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation. He served as associate editor of the journal blood and is the founding editor of blood advances. dr Negrin received his bachelor’s degree from the University of California at Berkeley and his medical degree Harvard University. He completed training in medicine and hematology University at Stanford and joined the faculty in 1990.
dr Negrin joins Appia Bio’s Scientific Advisory Board and Scientific Founders to advise the company, which is comprised of the following leaders in the fields of immunology, immuno-oncology and cell therapy technology:
Scientific Advisory Board
- Mitchell KronenbergPh.D., President and Chief Scientific Officer (CSO), La Jolla Institute for Immunology
- Anton RibasMD, Ph.D., Professor of Medicine, University of California, Los Angeles (UCLA) and Director of the Tumor Immunology Program at Jonsson Comprehensive Cancer Center
- Margo RobertsPh.D., former CSO, Kite Pharma and Lyell Immunopharma
- Irving WeissmanMD, Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia & DK Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Developmental Biology and, with kind permission, of Biology
- David BaltimorePh.D., Nobel Laureate, President Emeritus and Distinguished Professor of Biology, Caltech
- Pin Wang, Ph.D., Professor of Chemical Engineering and Materials Science and Biomedical Engineering, University of Southern California (U.S.C)
- Lily YangPh.D., Associate Professor of Microbiology, Immunology and Molecular Genetics, UCLA
About Appia Bio
Appia Bio is a pre-clinical stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on the discovery and development of engineered allogeneic cell therapies for a broad range of indications with a scalable technology platform that can improve patient access. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio harnesses the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) genetic engineering to generate CAR-engineered innate invariant natural killer T (CAR-NKT) -Cells from hematopoietic stem cells (HSCs). Visit www.appiabio.com for more information.
SOURCE Appia Bio